Emerging Issues in Vaccine for COVID

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 2629

Special Issue Editors


E-Mail Website
Guest Editor

E-Mail Website
Guest Editor
Department of Medicine, Surgery and Dentistry Department of Orthodontics, Università degli Studi di Milano - Fondazione IRCCS, Cà Granda, I-20133 Milan, Italy
Interests: SARS-CoV-2; COVID-19; bone regeneration; biomaterials
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy
Interests: N95 respirators; surgical mask; protective face masks; COVID-19; infection control; thermal infrared imaging; atmospheric plasma technique; X-ray microanalysis; laser; dental implants
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The recent advances in COVID-19 research include the newest findings regarding therapies, adjuvant supplements and vaccines against SARS-CoV-2 viral infection. These innovations seem to provide a reasonable improvement in the prognosis of patients since they cause a reduction in the clinical morbidity and mortality index. Moreover, the introduction of novel vaccines and devices is improving our perspectives regarding the capability of preventing COVID-19 and the efficiency of healthcare systems.

This Special Issue aims to present recent insights into vaccines, therapies, antivirals, and adjuvant supplements regarding the SARS-CoV-2 viral vector.

This Special Issue will consider the following types of paper for publication: in vivo original studies, human and animal studies, in vitro cells studies, biomolecular analysis, and reviews.

Prof. Dr. Francesco Inchingolo
Prof. Dr. Antonio Scarano
Dr. Gianna Dipalma
Prof. Dr. Gianluca M. Tartaglia
Dr. Felice Lorusso
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • COVID-19
  • human coronavirus
  • drug administration
  • vaccines
  • diagnostic tools
  • telemedicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 1911 KiB  
Article
Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers
by Alessio Danilo Inchingolo, Giuseppina Malcangi, Sabino Ceci, Assunta Patano, Alberto Corriero, Daniela Azzollini, Grazia Marinelli, Giovanni Coloccia, Fabio Piras, Giuseppe Barile, Vito Settanni, Antonio Mancini, Nicole De Leonardis, Grazia Garofoli, Giulia Palmieri, Ciro Gargiulo Isacco, Biagio Rapone, Megan Jones, Ioana Roxana Bordea, Gianluca Martino Tartaglia, Antonio Scarano, Felice Lorusso, Luigi Macchia, Angela Maria Vittoria Larocca, Silvio Tafuri, Giovanni Migliore, Nicola Brienza, Gianna Dipalma and Francesco Inchingoloadd Show full author list remove Hide full author list
Biomedicines 2022, 10(10), 2402; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines10102402 - 26 Sep 2022
Cited by 3 | Viewed by 2204
Abstract
The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of [...] Read more.
The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood type, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRna Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab controls were performed every 15th of the month continuously. However, the enrolled patients’ activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari “Aldo Moro” led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient. Full article
(This article belongs to the Special Issue Emerging Issues in Vaccine for COVID)
Show Figures

Figure 1

Back to TopTop